UnitedHealth has tumbled over the past three months. Why TD Cowen sees a recovery

TD Cowen upgraded UnitedHealth (UNH) to buy, raising its price target to $455 from $402, citing potential recovery in Optum Health and stronger earnings growth. Shares have fallen 14% in the past three months due to policy headwinds. Analyst Ryan Langston expects mid-high teens EPS growth through 2028, driven by Optum Health and other factors.

Original reporting
Published Nov 20, 2026, 12:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 2:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
UnitedHealth has tumbled over the past three months. Why TD Cowen sees a recovery — source image
Decision brief

The 30-second read

$UNHBullishHigh
01

Why it matters

The upgrade could trigger a short‑cover rally and attract new buying interest.

02

Market read

A fresh analyst upgrade with a substantial price‑target increase provides a clear catalyst for UNH and may influence health‑care sector sentiment.

03

What to watch

Potential regulatory scrutiny of Medicare Advantage could temper upside.

Relevance 7/10Novelty 7/10Timing: today

Background

UnitedHealth has fallen 14% over three months amid policy concerns; the upgrade argues the decline is overstated.

Company-level read

Ticker impact

$UNHBullishHigh confidence
Context

TD Cowen upgraded UnitedHealth to Buy and raised its price target to $455 from $402.

Expected impact

likely upward pressure as investors price in the new target

Evidence & confidence

The upgrade is a fresh, primary disclosure and the target implies ~38% upside from the current price.

Market effects

Positive for the health‑insurance sector as the upgrade may lift peers.

U.S. market may see modest buying in health‑care stocks.

Limited; primarily affects U.S. health‑care investors.

Counterpoint

Some investors may remain cautious given policy headwinds and pending Medicare anti‑fraud rule.

Key entities

  • TD Cowen

    Equity research firm issuing the upgrade.

  • UnitedHealth Group

    Health‑insurance and health‑services conglomerate (ticker UNH).

Related articles

$UNHMed

UnitedHealth Stock (UNH) Rises After the Healthcare Company Filed a Lawsuit Against the U.S. Government

UnitedHealth (UNH) stock rose 4.61% after filing a lawsuit against the U.S. government over a star rating drop by the Centers for Medicare & Medicaid Services, claiming improper measures were used. The company seeks higher ratings for 45 contracts, potentially increasing them by 0.5 to 1.5 stars. Analyst Ryan Langston upgraded UNH to Buy with a $455 price target, citing strong earnings growth.

$UNHMed

UnitedHealth sues US government over lowered Medicare Advantage star ratings

UnitedHealth Group sued the US government over its 2027 Medicare Advantage star ratings, claiming improper calculations could reduce bonus payments and patient benefits. The company, the largest Medicare Advantage insurer, said ratings for 45 contracts would rise if calculated correctly. CMS declined to comment. Other insurers, including CVS Health, have also sued over their ratings.

$UNHMed

Cowen Upgrades UNH and HUM Stocks to Buy and Lifts Price Targets After Healthcare Sell-Off. Here’s Why

Cowen upgraded UnitedHealth (UNH) and Humana (HUM) to Buy, citing strong earnings growth prospects. Analyst Ryan Langston raised UNH's price target to $455 and HUM's to $485. Both stocks rose in pre-market trading after a healthcare sector sell-off due to proposed CMS regulations. Cowen expects UNH's EPS to grow mid-high teens through 2028 and HUM's to reach $40.42 by 2028.

$UNHMed

UnitedHealth sues to reverse downgraded Medicare Advantage quality scores

UnitedHealth Group sued the U.S. government over lowered Medicare Advantage star ratings for 2027, joining 14 other insurers. The company, the largest Medicare Advantage insurer, claims the ratings calculation is inconsistent and unfairly reduces scores below bonus thresholds. Medicare Advantage plans are rated on a scale of one to five stars, with higher ratings earning bonus payments.